Theratechnologies Inc. (TSE:TH) had its target price trimmed by National Bank Financial from C$9.75 to C$8.75 in a research report sent to investors on Tuesday morning. The firm currently has an outperform rating on the stock. National Bank Financial also issued estimates for Theratechnologies’ FY2018 earnings at $0.14 EPS.

Separately, Scotiabank reduced their price target on shares of Theratechnologies from C$10.00 to C$9.25 and set an outperform rating for the company in a research report on Friday, October 6th.

Shares of Theratechnologies (TSE:TH) opened at C$6.43 on Tuesday. Theratechnologies has a one year low of C$2.61 and a one year high of C$8.72.

TRADEMARK VIOLATION NOTICE: This report was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/18/theratechnologies-inc-th-price-target-cut-to-c8-75-by-analysts-at-national-bank-financial.html.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

Receive News & Stock Ratings for Theratechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc. and related stocks with our FREE daily email newsletter.